Mutagen Sensitivity and Risk of Second Cancer in Younger Adults with Head and Neck Squamous Cell Cancer: 15-year Results

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2022 Mar 31

PMID 35357513

Authors

B Bukovszky

J Fodor

G Szekely

S Zs Kocsis

F Oberna

T Major

Z Takacsi-Nagy

C Polgar

Z Juranyi

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the mutagen sensitivity phenotype on the risk of second primary cancer (SPC) in patients with head and neck squamous cell carcinoma (HNSCC), and to estimate the long-term rate of SPC and the outcome with SPC.

Methods: A survey was made regarding SPC among 124 younger (≤ 50 years) adults with HNSCC who were enrolled in a pretreatment mutagen sensitivity investigation during 1996-2006. Mutagen sensitivity was assessed by exposing lymphocytes to bleomycin in vitro and quantifying the bleomycin-induced chromatid breaks per cell (b/c). Patients were classified as hypersensitive (> 1 b/c) or not hypersensitive (≤ 1 b/c).

Results: Mean follow-up time for all patients was 68 months (range: 5-288 months), and the 15-year cancer-specific survival was 15%. Twenty patients (16%) developed a SPC (15-year estimated rate: 41%), and half of them was hypersensitive. The crude rate of SPC for hypersensitive (n = 65) or not hypersensitive (n = 59) patients were 15 and 17%, respectively (p = 0.4272). The 15-year estimated rate of SPC for hypersensitive and not hypersensitive patients was 36 and 48%, respectively (p = 0.3743). Gender, UICC stages, anatomical sites of index cancer did not prove to be a significant risk factor for SPC. Forty-five percent of SPC developed after the 10-year follow-up. The 3‑year cancer-specific survival was 23% with SPC.

Conclusion: According to our findings, mutagen hypersensitivity was not associated with an increased SPC risk in HNSCC patients. Patients are at a lifelong risk of developing a SPC. Survival with SPC is very poor.

Citing Articles

De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a prospective multicenter phase II trial (DIREKHT Trial).

Haderlein M, von der Grun J, Balermpas P, Rodel C, Hautmann M, Steger F Front Oncol. 2024; 14:1447123.

PMID: 39224800 PMC: 11366634. DOI: 10.3389/fonc.2024.1447123.

Neck Node Squamous Cell Metastasis from Unknown Primary and Mutagen Sensitivity: A Case Series.

Bukovszky B, Fodor J, Szekely G, Toth E, Major T, Oberna F Case Rep Oncol. 2023; 16(1):1598-1605.

PMID: 38116298 PMC: 10730097. DOI: 10.1159/000533708.

Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.

Bhattacharjee B, Syeda A, Rynjah D, Hussain S, Chandra Bora S, Pegu P Front Pharmacol. 2023; 14:1174330.

PMID: 37205904 PMC: 10188950. DOI: 10.3389/fphar.2023.1174330.

Factors associated with the development of second primary tumours in head and neck cancer patients.

Salcedo-Bellido I, Requena P, Mateos R, Ortega-Rico C, Olmedo-Requena R, Lozano-Lorca M Eur J Cancer Care (Engl). 2022; 31(6):e13699.

PMID: 36117311 PMC: 9787413. DOI: 10.1111/ecc.13699.

References

Hsu T, Spitz M, Schantz S . Mutagen sensitivity: a biological marker of cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 1991; 1(1):83-9. View

Rennemo E, Zatterstrom U, Boysen M . Impact of second primary tumors on survival in head and neck cancer: an analysis of 2,063 cases. Laryngoscope. 2008; 118(8):1350-6. DOI: 10.1097/MLG.0b013e318172ef9a. View

Schottenfeld D, Gantt R, Wyner E . The role of alcohol and tobacco in multiple primary cancers of the upper digestive system, larynx and lung: a prospective study. Prev Med. 1974; 3(2):277-93. DOI: 10.1016/0091-7435(74)90037-1. View

Adjei Boakye E, Buchanan P, Hinyard L, Osazuwa-Peters N, Simpson M, Schootman M . Trends in the risk and burden of second primary malignancy among survivors of smoking-related cancers in the United States. Int J Cancer. 2019; 145(1):143-153. DOI: 10.1002/ijc.32101. View

Ben Arie G, Shafat T, Belochitski O, El-Saied S, Joshua B . Treatment Modality and Second Primary Tumors of the Head and Neck. ORL J Otorhinolaryngol Relat Spec. 2021; 83(6):420-427. PMC: 8686706. DOI: 10.1159/000513617. View

Szekely G, Remenar E, Kasler M, Gundy S . Does the bleomycin sensitivity assay express cancer phenotype?. Mutagenesis. 2002; 18(1):59-63. DOI: 10.1093/mutage/18.1.59. View

Cloos J, Leemans C, van der Sterre M, Kuik D, Snow G, Braakhuis B . Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2000; 9(7):713-7. View

Wu X, Gu J, Dong Q, Huang M, Do K, Hong W . Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res. 2006; 12(23):7194-201. DOI: 10.1158/1078-0432.CCR-06-0671. View

Schantz S, Spitz M, Hsu T . Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies. J Natl Cancer Inst. 1990; 82(22):1773-5. DOI: 10.1093/jnci/82.22.1773. View

10.

Cloos J, Braakhuis B, STEEN I, Copper M, de Vries N, Nauta J . Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer. 1994; 56(6):816-9. DOI: 10.1002/ijc.2910560610. View

11.

DAY G, Blot W, Shore R, McLaughlin J, Austin D, Greenberg R . Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst. 1994; 86(2):131-7. DOI: 10.1093/jnci/86.2.131. View

12.

Spitz M, Wu X, Jiang H, Hsu T . Mutagen sensitivity as a marker of cancer susceptibility. J Cell Biochem Suppl. 1996; 25:80-4. View

13.

Do K, Johnson M, Lee J, Wu X, Dong Q, Hong W . Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer. 2004; 101(12):2837-42. DOI: 10.1002/cncr.20714. View

14.

Li F, Montesano R . Interactions of cancer susceptibility genes and environmental carcinogens. American Association for Cancer Research (AACR)-International Agency for Research on Cancer (IARC) Joint Conference. Cancer Res. 1994; 54(15):4243-7. View

15.

Hsu T . Genetic instability in the human population: a working hypothesis. Hereditas. 1983; 98(1):1-9. DOI: 10.1111/j.1601-5223.1983.tb00574.x. View

16.

Lippman S, Hong W . Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radiat Oncol Biol Phys. 1989; 17(3):691-4. DOI: 10.1016/0360-3016(89)90126-0. View

17.

Minard C, Spitz M, Wu X, Hong W, Etzel C . Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer. 2006; 106(12):2636-44. DOI: 10.1002/cncr.21928. View

18.

Spitz M, Hoque A, Trizna Z, Schantz S, Amos C, King T . Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst. 1994; 86(22):1681-4. DOI: 10.1093/jnci/86.22.1681. View

19.

Bugter O, van Iwaarden D, van Leeuwen N, Nieboer D, Dronkers E, Hardillo J . A cause-specific Cox model for second primary tumors in patients with head and neck cancer: A RONCDOC study. Head Neck. 2021; 43(6):1881-1889. PMC: 8247881. DOI: 10.1002/hed.26666. View

20.

Schwartz L, Ozsahin M, Zhang G, Touboul E, De Vataire F, Andolenko P . Synchronous and metachronous head and neck carcinomas. Cancer. 1994; 74(7):1933-8. DOI: 10.1002/1097-0142(19941001)74:7<1933::aid-cncr2820740718>3.0.co;2-x. View